Identification of differential expressed PE exosomal miRNA in lung adenocarcinoma, tuberculosis, and other benign lesions.
Identification of differential expressed PE exosomal miRNA in lung adenocarcinoma, tuberculosis, and other benign lesions.
复制标题
肺腺癌、结核病和其他良性病变中差异表达的 PE 外泌体 miRNA 的鉴定
DOI：
10.1097/md.0000000000008361
复制
发表时间：
2017-11
期刊：
影响因子：
1.6
通讯作者：
Wang XZ
中科院分区：
文献类型：
--
作者：
Wang Y;Xu YM;Zou YQ;Lin J;Huang B;Liu J;Li J;Zhang J;Yang WM;Min QH;Li SQ;Gao QF;Sun F;Chen QG;Zhang L;Jiang YH;Deng LB;Wang XZ
摘要 胸腔积液（PE）是许多肺部和全身疾病（包括肺癌和结核病）的常见临床并发症。然而，临床上尚无有效的生物标志物来识别PE的病因。我们尝试通过深度测序和定量聚合酶链反应（qRT-PCR）研究肺腺癌（APE）、结核病（TPE）和其他良性病变（NPE）PE中差异表达的外泌体miRNA。结果，在3组PE中观察到171个分化的miRNA，并通过qRT-PCR验证了11个显着分化的外泌体miRNA。我们鉴定了 9 种 miRNA，包括 miR-205-5p、miR-483-5p、miR-375、miR-200c-3p、miR-429、miR-200b-3p、miR-200a-3p、miR-203a-3p 和 miR-141-3p，与 TPE 相比，它们优先出现在源自 APE 的外泌体中TPE 和 NPE 之间存在差异表达，而 miR-148a-3p、miR-451a 和 miR-150-5p 等 3 个 miRNA 在 TPE 和 NPE 之间存在差异表达。这些不同的 miRNA 谱可能有望作为 PE 鉴别诊断的生物标志物，并基于更大的队列进行更多验证。
Abstract Pleural effusion (PE) is a common clinical complication of many pulmonary and systemic diseases, including lung cancer and tuberculosis. Nevertheless, there is no clinical effective biomarker to identify the cause of PE. We attempted to investigate differential expressed exosomal miRNAs in PEs of lung adenocarcinoma (APE), tuberculous (TPE), and other benign lesions (NPE) by using deep sequencing and quantitative polymerase chain reaction (qRT-PCR). As a result, 171 differentiated miRNAs were observed in 3 groups of PEs, and 11 significantly differentiated exosomal miRNAs were validated by qRT-PCR. We identified 9 miRNAs, including miR-205-5p, miR-483-5p, miR-375, miR-200c-3p, miR-429, miR-200b-3p, miR-200a-3p, miR-203a-3p, and miR-141-3p which were preferentially represented in exosomes derived from APE when compared with TPE or NPE, while 3 miRNAs, including miR-148a-3p, miR-451a, and miR-150-5p, were differentially expressed between TPE and NPE. These different miRNAs profiles may hold promise as biomarkers for differential diagnosis of PEs with more validation based on larger cohorts.